Nanoparticle Based Vaccines
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 30 June 2024 | Viewed by 245
Special Issue Editors
Interests: lipid nanoparticle vaccines; liposome drug delivery; nanomedicine; mRNA vaccines; pDNA vaccines
Interests: nanovaccines; nanomedicine; analytical biotechnology
Interests: characterization of nanomedicines; nanomaterial components of mRNA vaccines; regulatory issues surrounding nanomedicines
Special Issue Information
Dear Colleagues,
The critical importance of nanoparticle-based vaccines has been demonstrated throughout the COVID-19 pandemic, with the rapid development and deployment of mRNA lipid nanoparticle vaccines to successfully combat the pandemic confirming the vast potential of nanoparticle-based vaccines. With this demonstrated success, it is anticipated that utilization of LNPs and other nanoparticles-based vaccines will be expanded to combat bacterial and viral diseases beyond COVID-19, to meet the challenges of future pandemics, and for therapeutic purposes such as cancer treatment.
Consequently, this Special Issue of Vaccines, “Nanoparticle Based Vaccines”, aims to highlight the most recent progress of nanoparticle-based vaccines. This Special Issue welcomes the submission of original research articles, short communications, and review articles with a focus on, but not limited to:
- Development of nanoparticle-based vaccines beyond those used for COVID-19. Nanoparticles systems could include but are not limited to novel formulations of LNPs, polymeric nanoparticles, subunit-based nanovaccines, exosome-based vaccines, or anticancer vaccines.
- Investigation of the impact of nanoparticle composition or formulation on vaccine stability and efficacy.
- Development of methodology or identification of issues with existing methodology for the characterization and assessment of nanoparticle-based vaccines.
- Standardization, regulation, and regulatory decision making for nanoparticle-based vaccines.
Dr. Michael Johnston
Dr. Luigi Calzolai
Dr. Anil Patri
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanoparticle-based vaccines
- vaccine delivery
- nanomedicine
- lipid nanoparticle vaccines
- anticancer vaccines
